Cognitive and behavioural impairment in Parkinson's disease

International Review of Psychiatry

Volumn 20, Issue 4, 2008, Pages 364-373

  Merims, Doron ^a   Freedman, Morris ^a,b,c  

^a ROTMAN RESEARCH INSTITUTE   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ANTIPARKINSON AGENT; APOMORPHINE; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MEMANTINE; MIRTAZAPINE; NEUROLEPTIC AGENT; PLACEBO; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALLELE; ALZHEIMER DISEASE; APATHY; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; COGNITIVE DEFECT; COMPREHENSION; DELUSION; DEMENTIA; DEPRESSION; DEPTH PERCEPTION; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; DYSKINESIA; ESSENTIAL TREMOR; GAIT DISORDER; GENETIC RISK; HALLUCINATION; HUMAN; IMPULSE CONTROL DISORDER; LANGUAGE DISABILITY; MEMORY DISORDER; MOOD CHANGE; MOOD DISORDER; NAUSEA; NEUROIMAGING; NEUROLEPTIC SENSITIVITY; PALLIDOTOMY; PARKINSON DISEASE; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SLEEP DISORDER; SPEECH DISORDER; TREMOR; VERBAL BEHAVIOR; VOMITING;

ANTIPARKINSON AGENTS; COGNITION DISORDERS; DEMENTIA; DISEASE PROGRESSION; HUMANS; INCIDENCE; LEWY BODIES; MEMANTINE; MENTAL DISORDERS; PALLIDOTOMY; PARKINSON DISEASE; PSYCHOTIC DISORDERS; RISK; SLEEP DISORDERS; VISUAL PERCEPTION;

EID: 54249140456     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260802095123     Document Type: Review

References (102)

1. Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A., & Kragh-Sorensen, P. (2003a). Prevalence and characteristics of dementia in Parkinson disease: An 8-year prospective study. Archives of Neurology, 60, 387-392.
2. Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A., Nielsen, H., & Kragh-Sorensen, P. (2001). Risk of dementia in Parkinson's disease: A community-based, prospective study. Neurology, 56, 730-736.
3. Aarsland, D., Larsen, J. P., Cummins, J. L., & Laake, K. (1999). Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: A community-based study. Archives of Neurology, 56, 595-601.
4. Aarsland, D., Larsen, J. P., Tandberg, E., & Laake, K. (2000). Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study. Journal of the American Geriatrics Society, 48, 938-942.
5. Aarsland, D., Litvan, I., Salmon, D., Galasko, D., Wentzel-Larsen, T., & Larsen, J. P. (2003b). Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: Comparison with progressive supranuclear palsy and Alzheimer's disease. Journal of Neurology, Neurosurgery & Psychiatry, 74, 1215-1220.
6. Aarsland, D., Perry, R., Brown, A., Larsen, J. P., & Ballard, C. (2005b). Neuropathology of dementia in Parkinson's disease: A prospective, community-based study. Annals of Neurology, 58, 773-776.
7. Aarsland, D., Perry, R., Larsen, J. P., McKeith, I. G., O'Brien, J. T., Perry, E. K., et al. (2005a). Neuroleptic sensitivity in Parkinson's disease and Parkinsonian dementias. Journal of Clinical Psychiatry, 66, 633-637.
8. Apaydin, H., Ahlskog, J. E., Parisi, J. E., Boeve, B. F., & Dickson, D. W. (2002). Parkinson disease neuropathology: Later-developing dementia and loss of the levodopa response. Archives of Neurology, 59, 102-112.
9. Ballard, C. G., Aarsland, D., McKeith, I., O'Brien, J., Gray, A., Cormack, F., et al. (2002). Fluctuations in attention: PD dementia versus DLB with Parkinsonism. Neurology, 59, 1714-1720.
10. Beatty, W. W. (2002). Cognition in a patient with very mild right-sided hemiparkinsonism. Neurocase, 8, 28-39.
11. Benito-Leon, J., Louis, E. D., & Bermejo-Pareja, F., Neurological Disorders in Central Spain Study Group, (2006). Elderly-onset essential tremor is associated with dementia. Neurology, 66, 1500-1505.
12. Boeve, B. F., Silber, M. H., Parisi, J. E., Dickson, D. W., Ferman, T. J., Benarroch, E. E., et al. (2003). Synucleinopathy pathology and REM sleep behavior disorder plus dementia or Parkinsonism. Neurology, 61, 40-45.
13. Bressan, R. A., & Crippa, J. A. (2005). The role of dopamine in reward and pleasure behaviour - review of data from preclinical research. Acta Psychiatrica Scandinavica, Supplementum, 427, 14-21.
14. Bronnick, K., Emre, M., Lane, R., Tekin, S., & Aarsland, D. (2007). Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. Journal of Neurology Neurosurgery Psychiatry, 78, 1064-1068.
15. Burton, E. J., McKeith, I. G., Burn, D. J., Williams, E. D., & O'Brien, J. T. (2004). Cerebral atrophy in Parkinson's disease with and without dementia: A comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain, 127, 791-800.
16. Cahn-Weiner, D. A., Grace, J., Ott, B. R., Fernandez, H. H., & Friedman, J. H. (2002). Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's disease. Neuropsychiatry, Neuropsychology, & Behavioral Neurology, 15, 79-87.
17. Camicioli, R., Oken, B. S., Sexton, G., Kaye, J. A., & Nutt, J. G. (1998). Verbal fluency task affects gait in Parkinson's disease with motor freezing. Journal of Geriatric Psychiatry & Neurology, 11, 181-185.
18. Colloby, S. J., Williams, E. D., Burn, D. J., Lloyd, J. J., McKeith, I. G., & O'Brien, J. T. (2005). Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. European Journal of Nuclear Medicine & Molecular Imaging, 32, 1176-1185.
19. Comella, C. L., Tanner, C. M., & Ristanovic, R. K. (1993). Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Annals of Neurology, 34, 710-714.
20. Cooper, J. A., Sagar, H. J., Jordan, N., Harvey, N. S., & Sullivan, E. V. (1991). Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain, 114, 2095-2122.
21. Cormack, F., Aarsland, D., Ballard, C., & Tovee, M. J. (2004). Pentagon drawing and neuropsychological performance in Dementia with Lewy bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia. International Journal of Geriatric Psychiatry, 4, 371-377.
22. Costa, A., Peppe, A., Dell'Agnello, G., Carlesimo, G. A., Murri, L., Bonuccelli, U., et al. (2003). Dopaminergic modulation of visual-spatial working memory in Parkinson's disease. Dementia & Geriatric Cognitive Disorders, 15, 55-66.
23. Cummings, J. L., Darkins, A., Mendez, M., Hill, M. A., & Benson, D. F. (1988). Alzheimer's disease and Parkinson's disease: Comparison of speech and language alterations. Neurology, 38, 680-684.
24. de la Fuente-Fernández, R., Nunez, M. A., & Lopez, E. (1999). The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. Clinical Neuropharmacology, 22, 226-230.
25. Dujardin, K., Defebvre, L., Krystkowiak, P., Blond, S., & Destee, A. (2001). Influence of chronic bilateral stimulation of the subthalamic nucleus on cognitive function in Parkinson's disease. Journal of Neurology, 248, 603-611.
26. Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., et al. (2004). Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine, 351, 2509-2518.
27. Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., et al. (2007). Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders, 22, 1689-1707.
28. Evans, A. H., Lawrence, A. D., Potts, J., MacGregor, L., Katzenschlager, R., Shaw, K., et al. (2006). Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry, 77, 317-321.
29. Fama, R., & Sullivan, E. V. (2002). Motor sequencing in Parkinson's disease: Relationship to executive function and motor rigidity. Cortex, 38, 753-767.
30. Fenelon, G., Thobois, S., Bonnet, A. M., Broussolle, E., & Tison, F. (2002). Tactile hallucinations in Parkinson's disease. Journal of Neurology, 249, 1699-1703.
31. Ferini-Strambi, L., Di Gioia, M. R., Castronovo, V., Oldani, A., Zucconi, M., & Cappa, S. F. (2004). Neuropsychological assessment in idiopathic REM sleep behavior disorder (RBD): Does the idiopathic form of RBD really exist? Neurology, 62, 41-45.
32. Firbank, M. J., Colloby, S. J., Burn, D. J., McKeith, I. G., & O'Brien, J. T. (2003). Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage, 2, 1309-1319.
33. Freedman, M., Rivoira, P., Butters, N., Sax, D. S., & Feldman, R. G. (1984). Retrograde amnesia in Parkinson's disease. Canadian Journal of Neurological Sciences, 11, 297-301.
34. Friedman, A., & Sienkiewicz, J. (1991). Psychotic complications of long-term levodopa treatment of Parkinson's disease. Acta Neurologica Scandinavica, 84, 111-113.
35. Fujii, C., Harada, S., Ohkoshi, N., Hayashi, A., & Yoshizawa, K. (2000). Cross-cultural traits for personality of patients with Parkinson's disease in Japan. American Journal of Medical Genetics, 96, 1-3.
36. Giladi, N., Treves, T. A., Paleacu, D., Shabtai, H., Orlov, Y., Kandinov, B., et al. (2000). Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. Journal of Neural Transmission, 107, 59-71.
37. Giladi, N., Weitzman, N., Schreiber, S., Shabtai, H., & Peretz, C. (2007). New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: The role of dopamine agonist treatment and age at motor symptoms onset. Journal of Psychopharmacology, 21, 501-506.
38. Gironell, A., Kulisevsky, J., Rami, L., Fortuny, N., Garcia-Sanchez, C., & Pascual-Sedano, B. (2003). Effects of pallidotomy and bilateral subthalamic stimulation on cognitive function in Parkinson disease. A controlled comparative study. Journal of Neurology, 250, 917-923.
39. Goetz, C. G., Burke, P. F., Leurgans, S., Berry-Kravis, E., Blasucci, L. M., Raman, R., et al. (2001). Genetic variation analysis in Parkinson disease patients with and without hallucinations: Case-control study. Archives of Neurology, 58, 209-213.
40. Harding, A. J., Broe, G. A., & Halliday, G. M. (2002). Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain, 125, 391-403.
41. Hausdorff, J. M., Balash, J., & Giladi, N. (2003). Effects of cognitive challenge on gait variability in patients with Parkinson's disease. Journal of Geriatric Psychiatry & Neurology, 16, 53-58.
42. Hausdorff, J. M., Cudkowicz, M. E., Firtion, R., Wei, J. Y., & Goldberger, A. L. (1998). Gait variability and basal ganglia disorders: Stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease. Movement Disorders, 13, 428-437.
43. Hausdorff, J. M., Doniger, G. M., Springer, S., Yogev, G., Simon, E. S., & Giladi, N. (2006). A common cognitive profile in elderly fallers and in patients with Parkinson's disease: The prominence of impaired executive function and attention. Experimental Aging Research, 32, 411-429.
44. Holroyd, S., Currie, L., & Wooten, G. F. (2001). Prospective study of hallucinations and delusions in Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry, 70, 734-738.
45. Hubble, J. P., Venkatesh, R., Hassanein, R. E., Gray, C., & Koller, W. C. (1993). Personality and depression in Parkinson's disease. Journal of Nervous & Mental Disease, 181, 657-662.
46. Inzelberg, R., Bonuccelli, U., Schechtman, E., Miniowich, A., Strugatsky, R., Ceravolo, R., et al. (2006). Association between amantadine and the onset of dementia in Parkinson's disease. Movement Disorders, 21, 1375-1379.
47. Inzelberg, R., Kipervasser, S., & Korczyn, A. D. (1998). Auditory hallucinations in Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry, 64, 533-535.
48. Jasinska-Myga, B., Opala, G., Goetz, C. G., Tustanowski, J., Ochudlo, S., Gorzkowska, A., et al. (2007). Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Archives of Neurology, 64, 261-265.
49. Jimenez-Jimenez, F. J., Mateo, D., & Gimenez-Roldan, S. (1992). Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: A case-control study. Movement Disorders, 7, 339-344.
50. Kleiner-Fisman, G., Fisman, D. N., Zamir, O., Dostrovsky, J. O., Sime, E., Saint-Cyr, J. A., et al. (2004). Subthalamic nucleus deep brain stimulation for Parkinson's disease after successful pallidotomy: Clinical and electrophysiological observations. Movement Disorders, 10, 1209-1214.
51. Koller, W. C., Glatt, S. L., Hubble, J. P., Paolo, A., Troster, A. I., Handler, M. S., et al. (1995). Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Annals of Neurology, 37, 242-245.
52. Lang, A. E., Lozano, A. M., Montgomery, E., Duff, J., Tasker, R., & Hutchinson, W. (1997). Posteroventral medial pallidotomy in advanced Parkinson's disease. New England Journal of Medicine, 337, 1036-1042.
53. Lange, K. W., Robbins, T. W., Marsden, C. D., James, M., Owen, A. M., & Paul, G. M. (1992). L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology, 107, 394-404.
54. Lemstra, A. W., Schoenmaker, N., Rozemuller-Kwakkel, A. J., & van Gool, W. A. (2006). The association of neuroleptic sensitivity in Lewy body disease with a false positive clinical diagnosis of Creutzfeldt-Jakob disease. International Journal of Geriatric Psychiatry, 21, 1031-1035.
55. Levy, G., Jacobs, D. M., Tang, M. X., Cote, L. J., Louis, E. D., Alfaro, B., et al. (2002). Memory and executive function impairment predict dementia in Parkinson's disease. Movement Disorders, 17, 1221-1226.
56. Litvan, I., Mohr, E., Williams, J., Gomez, C., & Chase, T. N. (1991). Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. Journal of Neurology, Neurosurgery & Psychiatry, 54, 25-29.
57. Lombardi, W. J., Woolston, D. J., Roberts, J. W., & Gross, R. E. (2001). Cognitive deficits in patients with essential tremor. Neurology, 57, 785-790.
58. Louis, E. D., & Frucht, S. J. (2007). Prevalence of essential tremor in patients with Parkinson's disease versus Parkinson-plus syndromes. Movement Disorders, 22, 1402-1407.
59. Louis, E. D., Honig, L. S., Vonsattel, J. P., Maraganore, D. M., Borden, S., & Moskowitz. (2005). Essential tremor associated with focal nonnigral Lewy bodies: A clinicopathologic study. Archives of Neurology, 62, 1004-1007.
60. Marder, K., Tang, M. X., Cote, L., Stern, Y., & Mayeux, R. (1995). The frequency and associated risk factors for dementia in patients with Parkinson's disease. Archives of Neurology, 52, 695-701.
61. Mattila, P. M., Rinne, J. O., Helenius, H., Dickson, D. W., & Roytta, M. (2000). Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathologica, 100, 285-290.
62. Mayeux, R., Saunders, A. M., Shea, S., Mirra, S., Evans, D., Roses, A. D., et al. (1998). Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's disease. New England Journal of Medicine, 338, 506-511.
63. McKeith, I., Del, S. T., Spano, P., Emre, M., Wesnes, K., Anand, R., et al. (2000). Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet, 356, 2031-2036.
64. McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., et al., & Consortium on DLB. (2005). Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology, 65, 1863-1872.
65. Melamed, E., Friedberg, G., & Zoldan, J. (1999). Psychosis: Impact on the patient and family. Neurology, 52, S14-16.
66. Melton, L. J., Leibson, C. L., Achenbach, S. J., Bower, J. H., Maraganore, D. M., Oberg, A. L., et al. (2006). Fracture risk after the diagnosis of Parkinson's disease: Influence of concomitant dementia. Movement Disorders, 21, 1361-1367.
67. Menza, M. A., Forman, N. E., Goldstein, H. S., & Golbe, L. I. (1990). Parkinson's disease, personality, and dopamine. Journal of Neuropsychiatry & Clinical Neurosciences, 2, 282-287.
68. Menza, M. A., Golbe, L. I., Cody, R. A., & Forman, N. E. (1993). Dopamine-related personality traits in Parkinson's disease. Neurology, 43, 505-508.
69. Merello, M., Nouzeilles, M. I., Cammarota, A., & Leiguarda, R. (1999). Effect of memantine (NMDA antagonist) on Parkinson's disease: A double-blind crossover randomized study. Clinical Neuropharmacology, 22, 273-276.
70. Merims, D., Shabtai, H., Korczyn, A. D., Peretz, C., Weizman, N., & Giladi, N. (2004). Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. Journal of Neural Transmission, 111, 1447-1453.
71. Molloy, S. A., Rowan, E. N., O'Brien, J. T., McKeith, I. G., Wesnes, K., & Burn, D. J. (2006). Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. Journal of Neurology, Neurosurgery & Psychiatry, 77, 1323-1328.
72. Morgan, J. C., diDonato, C. J., Iyer, S. S., Jenkins, P. D., Smith, J. R., & Sethi, K. D. (2006). Self-stimulatory behavior associated with deep brain stimulation in Parkinson's disease. Movement Disorders, 21, 283-285.
73. Mosimann, U. P., Mather, G., Wesnes, K. A., O'Brien, J. T., Burn, D. J., & McKeith, I. G. (2004). Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology, 63, 2091-2096.
74. Muslimovic, D., Post, B., Speelman, J. D., & Schmand, B. (2005). Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology, 65, 1239-1245.
75. Noe, E., Marder, K., Bell, K. L., Jacobs, D. M., Manly, J. J., & Stern, Y. (2004). Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Movement Disorders, 1, 60-67.
76. Olanow, C. W., Watts, R. L., & Koller, W. C. (2001). An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines. Neurology, 56, S1-S88.
77. Olson, E. J., Boeve, B. F., & Silber, M. H. (2000). Rapid eye movement sleep behaviour disorder: Demographic, clinical and laboratory findings in 93 cases. Brain, 123, 331-339.
78. Pacchetti, C., Manni, R., Zangaglia, R., Mancini, F., Marchioni, E., Tassorelli, C., et al. (2005). Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Movement Disorders, 11, 1439-1448.
79. Parsian, A., Racette, B., Goldsmith, L. J., & Perlmutter, J. S. (2002). Parkinson's disease and apolipoprotein E: Possible association with dementia but not age at onset. Genomics, 79, 458-461.
80. Paulson, G. W., & Dadmehr, N. (1991). Is there a premorbid personality typical for Parkinson's disease? Neurology, 41, 73-76.
81. Pillon, B., Ertle, S., Deweer, B., Sarazin, M., Agid, Y., & Dubois, B. (1996). Memory for spatial location is affected in Parkinson's disease. Neuropsychologia, 34, 77-85.
82. Poewe, W., Gerstenbrand, F., Ransmayr, G., & Plörer, S. (1983). Premorbid personality of Parkinson patients. Journal of Neural Transmission, Supplementum, 19, 215-224.
83. Pontone, G., Williams, J. R., Bassett, S. S., & Marsh, L. (2006). Clinical features associated with impulse control disorders in Parkinson disease. Neurology, 67, 1258-1261.
84. Rocca, W. A., Bower, J. H., Ahlskog, J. E., Elbaz, A., Grossardt, B. R., McDonnell, S. K., et al. (2007). Risk of cognitive impairment or dementia in relatives of patients with Parkinson disease. Archives of Neurology, 64, 1458-1464.
85. Sanchez-Ramos, J. R., Ortoll, R., & Paulson, G. W. (1996). Visual hallucinations associated with Parkinson disease. Archives of Neurology, 53, 1265-1268.
86. Schrag, A., Ben-Shlomo, Y., Brown, R., Marsden, C. D., & Quinn, N. (1998). Young-onset Parkinson's disease revisited - Clinical features, natural history, and mortality. Movement Disorders, 13, 885-894.
87. Schrag, A., Jahanshahi, M., & Quinn, N. (2000). What contributes to quality of life in patients with Parkinson's disease? Journal of Neurology, Neurosurgery & Psychiatry, 69, 308-312.
88. Shahed, J., & Jankovic, J. (2007). Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism & Related Disorders, 13, 67-76.
89. Smeding, H. M., Speelman, J. D., Koning-Haanstra, M., Schuurman, P. R., Nijssen, P., van, L. T., et al. (2006). Neuropsychological effects of bilateral STN stimulation in Parkinson disease: A controlled study. Neurology, 66, 1830-1836.
90. Starkstein, S. E., Bolduc, P. L., Mayberg, H. S., Preziosi, T. J., & Robinson, R. G. (1990). Cognitive impairments and depression in Parkinson's disease: A follow up study. Journal of Neurology, Neurosurgery & Psychiatry, 53, 597-602.
91. Starkstein, S. E., Mayberg, H. S., Leiguarda, R., Preziosi, T. J., & Robinson, R. G. (1992). A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry, 55, 377-382.
92. Starkstein, S. E., Petracca, G., Chemerinski, E., Teson, A., Sabe, L., Merello, M., et al. (1998). Depression in classic versus akinetic-rigid Parkinson's disease. Movement Disorders, 13, 29-33.
93. Szarfman, A., Doraiswamy, P. M., Tonning, J. M., & Levine, J. G. (2006). Association between pathologic gambling and Parkinsonian therapy as detected in the Food and Drug Administration Adverse Event database. Archives of Neurology, 63, 299-300.
94. Tandberg, E., Larsen, J. P., Aarsland, D., & Cummings, J. L. (1996). The occurrence of depression in Parkinson's disease. A community-based study. Archives of Neurology, 53, 175-179.
95. Troster, A. I., Paolo, A. M., Lyons, K. E., Glatt, S. L., Hubble, J. P., & Koller, W. C. (1995a). The influence of depression on cognition in Parkinson's disease: A pattern of impairment distinguishable from Alzheimer's disease. Neurology, 45, 672-676.
96. Troster, A. I., Stalp, L. D., Paolo, A. M., Fields, J. A., & Koller, W. C. (1995b). Neuropsychological impairment in Parkinson's disease with and without depression. Archives of Neurology, 52, 1164-1169.
97. Van Spaendonck, K. P., Berger, H. J., Horstink, M. W., Buytenhuijs, E. L., & Cools, A. R. (1996). Executive functions and disease characteristics in Parkinson's disease. Neuropsychologia, 34, 617-626.
98. Vendette, M., Gagnon, J. F., Decary, A., Massicotte-Marquez, J., Postuma, R. B., Doyon, J., et al. (2007). REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology, 69, 1843-1849.
99. Wakabayashi, K., Kakita, A., Hayashi, S., Okuizumi, K., Onodera, O., Tanaka, H., et al. (1998). Apolipoprotein E epsilon4 allele and progression of cortical Lewy body pathology in Parkinson's disease. Acta Neuropathologica, 95, 450-454.
100. Wilson, R. S., Kaszniak, A. W., Klawans, H. L., & Garron, D. C. (1980). High speed memory scanning in Parkinsonism. Cortex, 16, 67-72.
101. Witjas, T., Kaphan, E., Azulay, J. P., Blin, O., Ceccaldi, M., Pouget, J., et al. (2002). Nonmotor fluctuations in Parkinson's disease: Frequent and disabling. Neurology, 59, 408-413.
102. York, M. K., Dulay, M., Macias, A., Levin, H. S., Grossman, R., Simpson, R. & Jankovic, J. (2008). Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry, 79, 789-795 .